Transcatheter Aortic Valve Replacement with Evolut-R

Size: px
Start display at page:

Download "Transcatheter Aortic Valve Replacement with Evolut-R"

Transcription

1 Transcatheter Aortic Valve Replacement with Evolut-R Department of Transcatheter Heart Valves and 2 nd Cardiothoracic Surgery Clinic K. Spargias, M.Chrissoheris, A.Halapas, I. Nikolaou, S.Pattakos

2 Disclosures I and the HYGEIA Hospital «Heart Team» have received research and/or travel grants and/or lecture fees from: - Edwards Lifesciences - Medtronic - St Jude, Europe - ABBOTT Vascular, Europe HYGEIA Hospital Heart Team Cardiologists: A Chalapas, M Chrissoheris, K Spargias CT Surgeons: N Bouboulis, S Skardoutsos, A Tsolakis, S Pattakos Congenital Heart Disease: A Tzifa Anesthesiologists: C Nastoulis, I Nikolaou Vascular Surgeons: I Belos, S Kaliafas Radiologists: F Laspas, C Mourmouris Electrophysiologists: L Papavasileiou, G Zervopoulos, T Apostolopoulos

3 Building on the CoreValve Foundation Proven in More Than 65,000 Implants Worldwide Self-Expanding Frame Conforms and seals to the annulus The foundation for recapturability Supra Annular Valve Design Maximize flow and optimize coaptation Porcine Pericardial Tissue Thinness for low profile delivery Strength and pliability for long-term durability INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve Evolut R is approved. Medtronic, Inc All Rights Reserved.

4 CoreValve Evolut R System Recapturable valve and delivery catheter with loading system Catheter Delivery System 14Fr-equivalent profile Loading System Transcatheter Valve INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve Evolut R is approved. Medtronic, Inc All Rights Reserved.

5 Design Goals For Evolut R 1 Low Sheath OD to Femoral Artery Ratio (SFAR) Reduces risk of major vascular complications and improves access 2 Positioning Accuracy Key to achieving superior clinical outcomes, including PVL performance and conduction disturbances (Hayashida K., Lefevre T., Chevalier B.; et al. Transfemoral Aortic Valve Implantation; New Criteria to Predict Vascular Complications, J Am Coll Cardiol Intv ) (TcheTche, et. al. EuroIntervention 2012) 3 Annular sealing Reduces paravalvular leak Ease-of-use 4 CT images courtesy of Dr. Piazza and Prof. Lange, German Heart Center, Munich Germany INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve Evolut R is approved. Medtronic, Inc All Rights Reserved.

6 The Patient 83 year-old male, NYHA III dyspnea Severe aortic stenosis PG 91mmHg, MG 51mmHg, AVA 0.9cm 2 LVEF 65% Coronaries Patent stent in RCA, 60% mid LAD, conservative Comorbidities Parkinson RBBB/1AVB Euroscore 27%, STS 4.4%

7 Echocardiography

8 MDCT

9 Heart Team Discussion Severe aortic stenosis and symptoms Class I indication for replacement Due to advanced age and comorbidities decision for transcatheter aortic valve replacement, transfemoral approach Evolut R 29mm, without predilatation general anesthesia

10 Iliofemoral Angiography

11 Lowest Delivery Profile, 14Fr-Equivalent System with InLine Sheath across All Valve Sizes Improves Access and Reduces Risk of Major Vascular Complications* NOW Indicated for Minimum Transarterial Access Vessel Diameters 5.0 mm! Sheath to Femoral Artery Ratio (SFAR) great than 1.05 predicted higher rates of VARC major vascular complications. Hayashida K, et al. Transfemoral aortic valve implantation. JACC Intv 2011;4(8): INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve Evolut R is approved. Medtronic, Inc All Rights Reserved.

12 Insertion of Evolut R Delivery System

13 Initial Positioning

14 Positioning Accuracy: Self-Centering INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve Evolut R is approved. Medtronic, Inc All Rights Reserved.

15 Displacement over Aortic Annulus

16 Positioning Accuracy: Ability to Recapture and Reposition EnVeo R provides option to recapture and reposition up to three times before reaching the Point of No Recapture * Tactile Indicator ~ 2/3 Deployment Just Prior to Point of No Recapture ~ 80% Deployment* * Up to 80% deployment INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve Evolut R is approved. Medtronic, Inc All Rights Reserved.

17

18 Final Result Transient complete heart block Pacemaker implanted

19 Enhanced Annular Sealing: Extended Sealing Skirt 1 For Exceptional Valve Performance and Reduced Significant PVL 2 Outflow shortened and redesigned for improved anatomic fit Extended Sealing Skirt 1 Scalloped skirt creates longer landing zone for better sealing 1. Available on 26 and 29 mm sizes 2. Medtronic data on file. 23R comparison of CoreValve to CoreValve Evolut. Significant PVL defined as moderate PVL. INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve Evolut R is approved. Medtronic, Inc All Rights Reserved.

20 Echocardiography at 1 month Mean gradient 9mmHg, AR 0, AVA 1.7cm 2

21 In Summary Case demonstrates advantages of new Evolut-R Repositionable, resheathable, retreavable Minimal paravalvular leak Ability to implant without predilatation (with optional post-dilatation) Low delivery profile of 14F

CoreValve Evolut R Technology review and Clinical Results. Paul TL Chiam

CoreValve Evolut R Technology review and Clinical Results. Paul TL Chiam CoreValve Evolut R Technology review and Clinical Results Paul TL Chiam MBBS (S pore), MMed, MRCP (UK), FAMS FRCP (Edin), FESC (EU), FACC (USA), FSCAI (USA) Cardiologist Mount Elizabeth Hospital Singapore

More information

TAVI Technology and Procedural Changes

TAVI Technology and Procedural Changes TCT AP 2013 Seoul, South Korea April, 2013 TAVI Technology and Procedural Changes Eberhard Grube MD, FACC, FSCAI University Hospital, Dept of Medicine II, Bonn, Germany Hospital Alemão Oswaldo Cruz, São

More information

Ανεπάρκεια Τριγλώχινας Επιλογή Επεμβατικής Θεραπείας. Μ. Χρυσοχέρης Τμήμα Διαδερμικών Βαλβίδων ΔΘΚΑ ΥΓΕΙΑ

Ανεπάρκεια Τριγλώχινας Επιλογή Επεμβατικής Θεραπείας. Μ. Χρυσοχέρης Τμήμα Διαδερμικών Βαλβίδων ΔΘΚΑ ΥΓΕΙΑ Ανεπάρκεια Τριγλώχινας Επιλογή Επεμβατικής Θεραπείας Μ. Χρυσοχέρης Τμήμα Διαδερμικών Βαλβίδων ΔΘΚΑ ΥΓΕΙΑ Disclosures - Proctoring activities for Abbott Vascular, Edwards Lifesciences I and the HYGEIA Hospital

More information

Patient with low-flow low-gradient aortic stenosis and ischemic cardiomyopathy TAVR and possibly percutaneous revascularization

Patient with low-flow low-gradient aortic stenosis and ischemic cardiomyopathy TAVR and possibly percutaneous revascularization Patient with low-flow low-gradient aortic stenosis and ischemic cardiomyopathy TAVR and possibly percutaneous revascularization + K Spargias, MD, PhD THV Director Hygeia Hospital Disclosures - Proctor

More information

Progress In Transcatheter Aortic Valve Implantation

Progress In Transcatheter Aortic Valve Implantation Progress In Transcatheter Aortic Valve Implantation Gerald Yong MBBS (Hons) FRACP FSCAI Interventional Cardiologist Royal Perth Hospital Western Australia 4 th APCASH 8 th Sept 2013 Disclosure Statement

More information

30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study

30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study 30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the Study Stephan Windecker Department of Cardiology Bern University Hospital - INSELSPITAL

More information

Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40

Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40 Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human

More information

Echo evaluation for TAVR. From the General Cardiologist to the Interventional Echocardiologist

Echo evaluation for TAVR. From the General Cardiologist to the Interventional Echocardiologist Echo evaluation for TAVR From the General Cardiologist to the Interventional Echocardiologist Disclosures Proctoring activities for Abbott Vascular I and the HYGEIA Hospital «Heart Team» have received

More information

Portico (St. Jude Medical Inc, St.

Portico (St. Jude Medical Inc, St. Review Article Portico Transcatheter Heart Valve Apostolos Tzikas 1,2, Michael Chrissoheris 2, Antonios Halapas 2, Konstantinos Spargias 2 1 Interbalkan European Medical Centre, Thessaloniki, 2 Hygeia

More information

Aortic Stenosis. TAVR available devices Ioannis Iakovou, MD, PhD

Aortic Stenosis. TAVR available devices Ioannis Iakovou, MD, PhD Aortic Stenosis. TAVR available devices Ioannis Iakovou, MD, PhD Interventional Cardiology Onassis Cardiac Surgery Center Athens, Greece TAVI in 2018: Landscape TAVI is a Breakthrough Technology Dramatic

More information

Aortic Stenosis. TAVR available devices Ioannis Iakovou, MD, PhD

Aortic Stenosis. TAVR available devices Ioannis Iakovou, MD, PhD Aortic Stenosis. TAVR available devices Ioannis Iakovou, MD, PhD Interventional Cardiology Onassis Cardiac Surgery Center Athens, Greece Ομάδες εργασίας, Θεσσαλονίκη 2018 TAVI in 2018: Landscape TAVI is

More information

Transcatheter aortic valve implantation for severe aortic valve stenosis with the ACURATE neo2 valve system: 30-day safety and performance outcomes

Transcatheter aortic valve implantation for severe aortic valve stenosis with the ACURATE neo2 valve system: 30-day safety and performance outcomes All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions

More information

Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients?

Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients? Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients? Didier TCHETCHE, MD. Clinique PASTEUR, Toulouse, France, Conflicts of interest: -Consultant for Edwards LifeSciences

More information

Para-valvular Leak Closure

Para-valvular Leak Closure Para-valvular Leak Closure Antonios Chalapas, MD, PhD, FESC THV & Hygeia Hospital Heart Team Athens, Greece HYGEIA Hospital Heart Team Cardiologists: M Chrissoheris, Κ Papadopoulos, A Tzifa, A Chalapas,

More information

An Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.

An Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St. An Update on the Edwards TAVR Results Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St. Luke s Hospital Disclosures On the speaker s bureau for Endologix, TriVascular,

More information

ΔΙΑΔΕΡΜΙΚΗ ΑΝΣΙΚΑΣΑΣΑΗ ΑΟΡΣΙΚΗ ΒΑΛΒΙΔΑ αντιμετώπιση επιπλοκών ΠΕΣΡΟ. ΔΑΡΔΑ, MD, FESC IICE 2012

ΔΙΑΔΕΡΜΙΚΗ ΑΝΣΙΚΑΣΑΣΑΗ ΑΟΡΣΙΚΗ ΒΑΛΒΙΔΑ αντιμετώπιση επιπλοκών ΠΕΣΡΟ. ΔΑΡΔΑ, MD, FESC IICE 2012 ΔΙΑΔΕΡΜΙΚΗ ΑΝΣΙΚΑΣΑΣΑΗ ΑΟΡΣΙΚΗ ΒΑΛΒΙΔΑ αντιμετώπιση επιπλοκών ΠΕΣΡΟ. ΔΑΡΔΑ, MD, FESC IICE 2012 TAVR Technologies Current Generation Devices ~ 50,000 patients treated thru 2011 in > 500 interventional centers

More information

2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route

2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route Transcatheter Aortic Valve Implantation Asian perspective Speakers s name: Paul Chiam Paul TL Chiam MBBS, MRCP, FACC I have the following potential conflicts of interest to report: NONE Consultant National

More information

Edwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved

Edwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved Transcatheter Aortic Valve Replacement Symptomatic Aortic Stenosis Asymptomatic Juan Crestanello, MD Interim Director, Division of Cardiac Surgery Associate Professor Division of Cardiac Surgery The Ohio

More information

TAVI: Transapical Procedures

TAVI: Transapical Procedures Cardiology Update Davos TAVI: Transapical Procedures Volkmar Falk, MD University Hospital Zürich TA-AVI: antegrade, simple, safe The front door approach! Transapical TAVI Technical advantages of TA approach

More information

How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min

How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min 2016 ASE State of the Art Echocardiography Course Tucson, AZ How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, 2016 11:00 11:25 PM 25 min 1 M U H A M E D S A R I Ć, M D, P H D

More information

Para-valvular Leak Closure

Para-valvular Leak Closure Para-valvular Leak Closure Antonios Halapas, MD, PhD, FESC THV & Hygeia Hospital Heart Team Athens, Greece Disclosures I and the HYGEIA Hospital «Heart Team» have received research and travel grants from

More information

TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy

TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy Alan Zajarias, MD FACC Structural Interventional Fellowship Director Associate Professor Medicine Cardiovascular Division

More information

Transcatheter Aortic Valve Implantation (TAVI) - 5 important lessons learnt from HK experiences Michael KY Lee

Transcatheter Aortic Valve Implantation (TAVI) - 5 important lessons learnt from HK experiences Michael KY Lee Transcatheter Aortic Valve Implantation (TAVI) - 5 important lessons learnt from HK experiences Michael KY Lee Queen Elizabeth Hospital, Hong Kong President, HKSTENT APCASH 2013 SJ Park TAVI Summit 2013

More information

Trans Catheter Aortic Valve Replacement

Trans Catheter Aortic Valve Replacement Trans Catheter Aortic Valve Replacement Satish K Surabhi, MD,FACC,FSCAI Medical Director, Cardiac Cath Labs AnMed Health Heart and Vascular Care No financial conflict of interest related to this talk Will

More information

TAVI IN BICUSPID AOV AND VALVE-IN-VALVE

TAVI IN BICUSPID AOV AND VALVE-IN-VALVE TAVI IN BICUSPID AOV AND VALVE-IN-VALVE Petros S. Dardas, MD, FESC St Lukes Hospital Thessaloniki, GREECE 6o ΣΥΝΕΔΡΙΟ ΔΙΑΚΑΘΕΤΗΡΙΑΚΗΣ ΘΕΡΑΠΕΙΑΣ ΚΑΡΔΙΑΚΩΝ ΒΑΛΒΙΔΟΠΑΘΕΙΩΝ ΑΘΗΝΑ 2017 BICUSPID AOV Surgical

More information

PVL Assessment. Is paravalvular regurgitation after TAVR still an important consideration in 2018?

PVL Assessment. Is paravalvular regurgitation after TAVR still an important consideration in 2018? Joint Meeting 1 Aortic and Mitral Club Chairpersons: S.Adamopoulos, M. Vavuranakis, L. Michalis, P. Nihoyannopoulos PVL Assessment. Is paravalvular regurgitation after TAVR still an important consideration

More information

Imaging in TAVI. Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013

Imaging in TAVI. Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013 Imaging in TAVI Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013 Research grants: Medtronic, Biotronik, Boston Scientific, St Jude, BMS imaging, GE Healthcare,

More information

Transcatheter Aortic Valve Implantation (TAVI)

Transcatheter Aortic Valve Implantation (TAVI) Transcatheter Aortic Valve Implantation (TAVI) QEH Registry A Multidisciplinary Team Approach Michael KY Lee 1, LK Chan 1, KC Chan 1, KT Chan 1, SF Chui 1, HS Ma 1, CY Wong 1, CS Chiang 1, P Li 1, CB Lam

More information

TAVR for low-risk patients in 2017: not so fast.

TAVR for low-risk patients in 2017: not so fast. TAVR for low-risk patients in 2017: not so fast. Enrico Ferrari, MD, FETCS Cardiac Surgery Department Cardiocentro Ticino Foundation Lugano, Switzerland Conflicts of Interest Consultant and proctor for

More information

CoreValve in a Degenerative Surgical Valve

CoreValve in a Degenerative Surgical Valve CoreValve in a Degenerative Surgical Valve Ran Kornowski, MD, FESC, FACC Chairman Department of Cardiology Rabin Medical Center, Petach Tikva, Israel Disclosure Statement of Financial Interest I, Ran Kornowski,

More information

Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data

Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Echo Florida 2013 Jonathan J. Passeri, M.D. Co-Director, Heart Valve Program Director,

More information

Transcatheter aortic valves in aortic regurgitation Gry Dahle Dept of Cardiothoracic- and vascular surgery Rikshospitalet, Oslo University Hospital,

Transcatheter aortic valves in aortic regurgitation Gry Dahle Dept of Cardiothoracic- and vascular surgery Rikshospitalet, Oslo University Hospital, Transcatheter aortic valves in aortic regurgitation Gry Dahle Dept of Cardiothoracic- and vascular surgery Rikshospitalet, Oslo University Hospital, Oslo, Norway Aortic regurgitation Prevalence in Framingham

More information

Transcatheter Aortic Valve Replacement

Transcatheter Aortic Valve Replacement Transcatheter Aortic Valve Replacement Jesse Jorgensen, MD Medical Director, Cardiac Catheterization Laboratory Greenville Health System Greenville, South Carolina, USA January 30, 2016 Aortic Stenosis

More information

Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system

Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system Preliminary Results: Acute and 1-year Outcomes Ganesh Manoharan, MBBCh, MD, FRCP Consultant Cardiologist

More information

3 years after introduction of TAVI in QEH. Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong

3 years after introduction of TAVI in QEH. Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong 3 years after introduction of TAVI in QEH Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong HA Convention 2014 Introduction Aortic Stenosis most common valvular heart disease

More information

Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute

Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Despite a 33 fold growth in the first five years, there is still tremendous variability among penetration in different countries

More information

Pacemaker rates Second generation TAVI Devices

Pacemaker rates Second generation TAVI Devices Pacemaker rates Second generation TAVI Devices Florian Krackhardt, M.D. Department of Cardiology Charité Campus Virchow-Klinikum University Hospital Berlin, Germany TAVI The future s looking very positive

More information

(EU), FACC (USA), FSCAI (USA)

(EU), FACC (USA), FSCAI (USA) How to reduce vascular complications of TAVI Paul TL Chiam MBBS (S pore), MMed, MRCP (UK), FAMS FRCP (Edin), FESC (EU), FACC (USA), FSCAI (USA) Cardiologist Mount Elizabeth Hospital Singapore Definition

More information

Vascular complications of embolized core valve

Vascular complications of embolized core valve Vascular complications of embolized core valve Suhail Dohad, MD FACC Director of Endovascular services, Interventional Cardiology Cardiovascular Research Foundation of Southern California, CVMG Director

More information

Valve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D.

Valve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D. Valve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D. Professor, Thoracic and Cardiovascular Surgery University of Florida klodell@surgery.ufl.edu Disclosures

More information

Jonathon Leipsic MD FRCPC FSCCT. Vice Chairman of Radiology University of British Columbia. Disclosures

Jonathon Leipsic MD FRCPC FSCCT. Vice Chairman of Radiology University of British Columbia. Disclosures Jonathon Leipsic MD FRCPC FSCCT Vice Chairman of Radiology University of British Columbia Disclosures Speaker s bureau: GE Healthcare and Edwards LifeSciences Grant Support- CIHR, GE Healthcare Advisory

More information

How to manage TAVI related vascular complications. Paul TL Chiam MBBS, FRCP, FESC, FACC, FSCAI

How to manage TAVI related vascular complications. Paul TL Chiam MBBS, FRCP, FESC, FACC, FSCAI How to manage TAVI related vascular complications Paul TL Chiam MBBS, FRCP, FESC, FACC, FSCAI Definition VARC-2 consensus statement Complications caused by: Wire Catheter Anything related to vascular access

More information

Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update

Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update Howard J Broder MD Interventional Cardiology DaVita Medical Group/ Healthcare Partners Cardiology Disclosures for Howard J Broder

More information

Percutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update

Percutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update Percutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update T. Lefèvre Natural History of Aortic Stenosois 100 Latent period Survival (%) 80 60 40 20 Symptoms Average Age Death 0 40 50

More information

TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre

TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre Disclosure St. Jude Medical: Consultant and Proctor Edwards Lifesciences: Proctor Medtronic: Research

More information

Evolut R in bicuspid valve anatomies

Evolut R in bicuspid valve anatomies Evolut R in bicuspid valve anatomies U. Gerckens MD University of Rostock, Germany Potential conflicts of interest Speaker's name: Ulrich Gerckens I have the following potential conflicts of interest to

More information

I will not discuss off label use or investigational use in my presentation.

I will not discuss off label use or investigational use in my presentation. I will not discuss off label use or investigational use in my presentation. Surgical valves Design and Durability Testing Potential Concerns Real Practice 1952-1962 1963-1966 1967-1969 1969-1977 1977-1984

More information

Comments restricted to Sapien and Corevalve 9/12/2016. Disclosures: Core Lab contracts with Edwards Lifesciences, Middlepeak, Medtronic

Comments restricted to Sapien and Corevalve 9/12/2016. Disclosures: Core Lab contracts with Edwards Lifesciences, Middlepeak, Medtronic Para-ValvularRegurgitation post TAVR: Predict, Prevent, Quantitate, Manage Linda D. Gillam, MD, MPH, FACC, FASE Chair, Department of Cardiovascular Medicine Morristown Medical Center/Atlantic Health System

More information

Optimal Imaging Technique Prior to TAVI -Echocardiography-

Optimal Imaging Technique Prior to TAVI -Echocardiography- 2014 KSC meeting Optimal Imaging Technique Prior to TAVI -Echocardiography- Geu-Ru Hong, M.D. Ph D Associate Professor of Medicine Division of Cardiology, Severance Cardiovascular Hospital Yonsei University

More information

Transcatheter Aortic Valve Replacement With the St. Jude Medical Portico Valve

Transcatheter Aortic Valve Replacement With the St. Jude Medical Portico Valve Journal of the American College of Cardiology Vol. 60, No. 7, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.045

More information

transcatheter heart valve: THV TAVI transcatheter aortic valve implantation

transcatheter heart valve: THV TAVI transcatheter aortic valve implantation transcatheter heart valve: THV TAVI transcatheter aortic valve implantation Hideki OSHIMA 1. はじめに transcatheter heart valve: THV 1) transcatheter aortic valve implantation: TAVI transcatheter mitral valve

More information

Ian T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FAPSIC. Monash HEART, Monash Health & Monash University Melbourne, Australia

Ian T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FAPSIC. Monash HEART, Monash Health & Monash University Melbourne, Australia Two-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results From the REPRISE II

More information

Aortic valve implantation using the femoral and apical access: a single center experience.

Aortic valve implantation using the femoral and apical access: a single center experience. Aortic valve implantation using the femoral and apical access: a single center experience. R. Hoffmann, K. Brehmer, R. Koos, R. Autschbach, N. Marx, G. Dohmen Rainer Hoffmann, University Aachen, Germany

More information

TAVI EN INSUFICIENCIA AORTICA

TAVI EN INSUFICIENCIA AORTICA TAVI EN INSUFICIENCIA AORTICA Cesar Moris Profesor Cardiología Director Departamento del Corazón Hospital Universitario Central de Asturias Universidad de Oviedo OVIEDO -- ESPAÑA CONFLICTO DE INTERESES

More information

The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health. Adam J. Saltzman, MD Cardiovascular Care Center

The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health. Adam J. Saltzman, MD Cardiovascular Care Center The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health Adam J. Saltzman, MD Cardiovascular Care Center Southcoast Health Disclosures Edwards Lifesciences: speaking honorarium Outline

More information

Image Assistance in TAVI Why CT? Won-Jang Kim, MD, PhD Clinical Assistant Professor of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea

Image Assistance in TAVI Why CT? Won-Jang Kim, MD, PhD Clinical Assistant Professor of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea Image Assistance in TAVI Why CT? Won-Jang Kim, MD, PhD Clinical Assistant Professor of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea Major Uses of CT in TAVI Ileofemoral Patient Arterial

More information

Successful percutaneous treatment of late-onset femoral pseudoaneurysm after transcatheter, aortic valve implantation procedure

Successful percutaneous treatment of late-onset femoral pseudoaneurysm after transcatheter, aortic valve implantation procedure Case Report Page 1 of 5 Successful percutaneous treatment of late-onset femoral pseudoaneurysm after transcatheter, aortic valve implantation procedure Murat Celik, Uygar Cagdas Yuksel Correspondence to:

More information

Eberhard Grube MD, FACC, FSCAI

Eberhard Grube MD, FACC, FSCAI TAVI - Summit 2012 Seoul, September 8, 2012 Next Generation TAVI Systems Eberhard Grube MD, FACC, FSCAI University Hospital, Dept of Medicine II, Bonn, Germany Hospital Alemão Oswaldo Cruz, São Paulo,

More information

Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison

Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison Mauri, V. et al.: Circ Cardiovasc Interv. 2017;10:e005013 All trademarks are the property

More information

Update on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center

Update on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center Update on Percutaneous Therapies for Structural Heart Disease William Thomas MD Director of Structural Heart Program Tucson Medical Center NCVH 2014- Tucson Disclosure of Financial Interest Research: Stock

More information

Results of Transfemoral Transcatheter Aortic Valve Implantation

Results of Transfemoral Transcatheter Aortic Valve Implantation Results of Transfemoral Transcatheter Aortic Valve Implantation Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division

More information

Successful Transfemoral Edwards Sapien Aortic. Valve Implantation in a Patient with Previous. Mitral Valve Replacement

Successful Transfemoral Edwards Sapien Aortic. Valve Implantation in a Patient with Previous. Mitral Valve Replacement Advanced Studies in Medical Sciences, Vol. 2, 2014, no. 1, 37-45 HIKARI Ltd, www.m-hikari.com http://dx.doi.org/10.12988/asms.2014.31213 Successful Transfemoral Edwards Sapien Aortic Valve Implantation

More information

TAVI: Nouveaux Horizons

TAVI: Nouveaux Horizons TAVI: Nouveaux Horizons EUAPI580i 432HQ14NP02353 Institut de Cardiologie de la Pitié-Salpêtrière jean-philippe.collet@psl.aphp.fr www.action-coeur.org Objectifs Les recommandations Le TAVI en chiffre La

More information

Transcatheter Aortic Valve Implantation Present Status and Perspectives

Transcatheter Aortic Valve Implantation Present Status and Perspectives Transcatheter Aortic Valve Implantation Present Status and Perspectives Angioplasty Summit TCTAP 2010 Alain Cribier, MD University of Rouen, France Transcatheter Aortic Valve Implantation has entered the

More information

Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School

Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School Aortic Stenosis: Current State of Percutaneous Therapies, Emerging Technologies and Future Directions Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of

More information

RANDOMISED TRIALS TAVI WITH SAVR STEPHAN WINDECKER AORTIC VALVE DISEASE COMPARING

RANDOMISED TRIALS TAVI WITH SAVR STEPHAN WINDECKER AORTIC VALVE DISEASE COMPARING AORTIC VALVE DISEASE RANDOMISED TRIALS COMPARING TAVI WITH SAVR STEPHAN WINDECKER DEPARTMENT OF CARDIOLOGY SWISS CARDIOVASCULAR CENTER AND CLINICAL TRIALS UNIT BERN BERN UNIVERSITY HOSPITAL, SWITZERLAND

More information

TAVR: Echo Measurements Pre, Post And Intra Procedure

TAVR: Echo Measurements Pre, Post And Intra Procedure 2017 ASE Florida, Orlando, FL October 10, 2017 8:00 8:25 AM 25 min TAVR: Echo Measurements Pre, Post And Intra Procedure Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology Echo Lab Associate

More information

SAPIEN 3 Sizing Considerations:

SAPIEN 3 Sizing Considerations: SAPIEN 3 Sizing Considerations: Oversizing, Undersizing, or Volume reduction? John Webb MD St Paul s Hospital University of British Columbia Vancouver Disclosure Statement of Financial Interest Within

More information

Andrzej Ochala, MD Medical University of Silesia, Katowice, Poland

Andrzej Ochala, MD Medical University of Silesia, Katowice, Poland Andrzej Ochala, MD Medical University of Silesia, Katowice, Poland Bicuspid aortic valve o Most common congenital heart disease in adults (1% - 2%) o AS is the most common complication of BAV o Patophysiology

More information

1-YEAR OUTCOMES FROM JOHN WEBB, MD

1-YEAR OUTCOMES FROM JOHN WEBB, MD 1-YEAR OUTCOMES FROM JOHN WEBB, MD ON BEHALF OF THE SAPIEN 3 INVESTIGATORS UNIVERSITY OF BRITISH COLUMBIA VANCOUVER, CANADA Potential conflicts of interest Speaker's name: John Webb I have the following

More information

Current Evidence in TAVI patients using ACURATE and LOTUS valves

Current Evidence in TAVI patients using ACURATE and LOTUS valves Current Evidence in TAVI patients using ACURATE and LOTUS valves Giuseppe Tarantini, MD, PhD, FESC, Professor and Director of Interventional Cardiology University of Padua GISE President Potential conflicts

More information

Emerging Transcatheter Aortic Valve Technologies

Emerging Transcatheter Aortic Valve Technologies East Meets West: Emerging Transcatheter Aortic Valve Technologies Emerging valve systems and iterative technologies from around the world and how they could shape global practice going forward. BY FEDERICO

More information

Mitral Programme Update

Mitral Programme Update Direct Flow Medical Innovations in the Aortic and Mitral Programmes Mitral Programme Update Azeem Latib MD EMO-GVM Centro Cuore Columbus and San Raffaele Scientific Institute, Milan, Italy Potential conflicts

More information

Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval?

Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval? Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval? Update from PARTNER EU and SOURCE Registries T. Lefèvre Disclosure Statement Cardiologist Interventional cardiologist 1 st PABV in

More information

Transcatheter Valve-In-Valve Implantation for Failed Balloon-Expandable Transcatheter Aortic Valves

Transcatheter Valve-In-Valve Implantation for Failed Balloon-Expandable Transcatheter Aortic Valves JACC: CARDIOVASCULAR INTERVENTIONS VOL. 5, NO. 5, 2012 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2012.03.008 Transcatheter

More information

Dr. Jean-Claude Laborde

Dr. Jean-Claude Laborde Medtronic CoreValve Experience Alternative Access (Subclavian) and Technology Evolution of the Medtronic CoreValve TAVI System Dr. Jean-Claude Laborde Glenfield Hospital, Leicester, U.K. St George Hospital,

More information

TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR

TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR Saibal Kar, MD, FACC, FAHA, FSCAI Professor of Medicine Director of Interventional Cardiac Research Smidt Heart Institute, Cedars-Sinai

More information

TAVR: Current Valve Types. Patient Selection

TAVR: Current Valve Types. Patient Selection TAVR: Current Valve Types. Patient Selection Oscar A. Mendiz.MD.FACC.FSCAI Director Cardiology & Cardiovascular Institute (ICyCC) Chief Interventional Cardiology Department Board of Directors Hospital

More information

Nouvelles indications/ Nouvelles valves

Nouvelles indications/ Nouvelles valves Nouvelles indications/ Nouvelles valves Sadra Lotus Valve system Boston Scientific A. Tirouvanziam Institut Thorax Nantes SH-31314-AC Sept 2012 Slide 1 of 53 SH-31314-AC Sept 2012 Slide 2 of 53 Building

More information

A review of the complications associated with Transcatheter Aortic Valve Implantation.

A review of the complications associated with Transcatheter Aortic Valve Implantation. A review of the complications associated with Transcatheter Aortic Valve Implantation. Dr Conor McQuillan Transcatheter Aortic Valve Implantation (TAVI) has become the standard of care for treating elderly,

More information

Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris

Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives Bernard Iung Bichat Hospital, Paris Euro Heart Survey on Valvular Diseases 3547 Patients with Native Valve Disease n= 1250 1000

More information

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III On Behalf of the CoreValve US Clinical Investigators

More information

30-day Outcomes of The CENTERA Trial a New Self-Expanding Transcatheter Heart Valve. Didier Tchétché, MD On Behalf of the CENTERA Investigators

30-day Outcomes of The CENTERA Trial a New Self-Expanding Transcatheter Heart Valve. Didier Tchétché, MD On Behalf of the CENTERA Investigators 30-day Outcomes of The CENTERA Trial a New Self-Expanding Transcatheter Heart Valve Didier Tchétché, MD On Behalf of the CENTERA Investigators Speaker's name: Didier Tchétché, MD I have the following potential

More information

Transcatheter Aortic Valve Implantation Management of risks and complications

Transcatheter Aortic Valve Implantation Management of risks and complications Transcatheter Aortic Valve Implantation Management of risks and complications TAVI Summit, Seoul, Korea, Spetember 3rd, 2011 Alain Cribier University of Rouen, France Complications of TAVI Depending on

More information

Update on a Tethered Transapical Device for TMVR Vinay Badhwar, MD

Update on a Tethered Transapical Device for TMVR Vinay Badhwar, MD Update on a Tethered Transapical Device for TMVR Vinay Badhwar, MD Gordon F. Murray Professor and Chairman Department of Cardiovascular & Thoracic Surgery WVU Heart and Vascular Institute West Virginia

More information

Treatment of Bio-Prosthetic Valve Deterioration Using Transcatheter Techniques

Treatment of Bio-Prosthetic Valve Deterioration Using Transcatheter Techniques Treatment of Bio-Prosthetic Valve Deterioration Using Transcatheter Techniques Pablo Codner, Abid Assali, Hanna Vaknin-Assa, Katia Orvin, Ram Sharony, Leor Perl, Gabriel Greenberg, Marina Kupershmidt,

More information

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular

More information

SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes

SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes Howard C. Herrmann, MD on behalf of The PARTNER II Trial

More information

My Choice For Percutaneous Mitral Valve Replacement. Jose Luis Navia, MD.

My Choice For Percutaneous Mitral Valve Replacement. Jose Luis Navia, MD. My Choice For Percutaneous Mitral Valve Replacement Jose Luis Navia, MD. Disclosure Edwards Lifescienses St. Jude Medical MAQUET NaviGate Consultant, Investigator Consultant, Investigator Consultant, Investigator

More information

Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)

Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine

More information

Le TAVI pour tout le monde?

Le TAVI pour tout le monde? Le TAVI pour tout le monde? Thierry Lefèvre Institut Cardiovasculaire Paris Sud, Massy Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an affiliation or

More information

Istanbul Course of Interventional Cardiology Istanbul, June 11, 2011

Istanbul Course of Interventional Cardiology Istanbul, June 11, 2011 Istanbul Course of Interventional Cardiology Istanbul, June 11, 2011 Within the past 12 months, the presenter or their spouse/partner have had a financial interest/arrangement or affiliation with the organization(s)

More information

First Transfemoral Aortic Valve Implantation In Bulgaria - Crossing The Valve With The Device Is Not Always

First Transfemoral Aortic Valve Implantation In Bulgaria - Crossing The Valve With The Device Is Not Always ISPUB.COM The Internet Journal of Cardiology Volume 9 Number 2 First Transfemoral Aortic Valve Implantation In Bulgaria - Crossing The Valve With The Device Is Not T D, J P. Citation T D, J P.. First Transfemoral

More information

Outcomes in the Commercial Use of Self-expanding Prostheses in Transcatheter Aortic Valve Replacement: A Comparison of the Medtronic CoreValve and

Outcomes in the Commercial Use of Self-expanding Prostheses in Transcatheter Aortic Valve Replacement: A Comparison of the Medtronic CoreValve and Outcomes in the Commercial Use of Self-expanding Prostheses in Transcatheter Aortic Valve Replacement: A Comparison of the Medtronic CoreValve and Evolut R platforms in the Society of Thoracic Surgeons/American

More information

Planning for Transcatheter Aortic Valve Replacement

Planning for Transcatheter Aortic Valve Replacement WHAT WOULD YOU DO? Planning for Transcatheter Aortic Valve Replacement MODERATOR: MAURICIO G. COHEN, MD, FACC, FSCAI PANEL: SANTIAGO GARCIA, MD, FACC, FSCAI; WILLIAM O NEILL, MD; AND MOLLY SZERLIP, MD,

More information

7 th Conference of Transcatheter Heart Valve Therapies

7 th Conference of Transcatheter Heart Valve Therapies 7 th Conference of Transcatheter Heart Valve Therapies May 18-19, 2018, Athens Hilton Athens, Greece Course Directors Stratis Pattakos MD Konstantinos Spargias MD Panos Vardas MD Co-Directors Nick Bouboulis

More information

Conflicts of interests

Conflicts of interests Update in Interventional Cardiology for the Internist Transcatheter valve therapies Dr Vaikom S Mahadevan Director of Structural and Adult Congenital Interventions William W Parmley Endowed Chair in Cardiology

More information

Transcatheter Aortic Valve Replacement With a New Self-Expanding Transcatheter Heart Valve and Motorized Delivery System

Transcatheter Aortic Valve Replacement With a New Self-Expanding Transcatheter Heart Valve and Motorized Delivery System JACC: CARDIOVASCULAR INTERVENTIONS VOL. 6, NO. 3, 2013 2013 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2013.01.129

More information

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More? CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology

More information

From CoreValve to Evolut PRO: Reviewing the Journey of Self-Expanding Transcatheter Aortic Valves

From CoreValve to Evolut PRO: Reviewing the Journey of Self-Expanding Transcatheter Aortic Valves Cardiol Ther (2017) 6:183 192 DOI 10.1007/s40119-017-0100-z REVIEW From CoreValve to Evolut PRO: Reviewing the Journey of Self-Expanding Transcatheter Aortic Valves Dhruv Mahtta. Islam Y. Elgendy. Anthony

More information